GLP-1 Receptor Agonists: A Complete Clinical Guide

1. The GLP-1 system at a glance

GLP-1 receptor agonists are pharmacological mimics of the endogenous incretin hormone glucagon-like peptide-1. The native peptide is released from intestinal L-cells in response to nutrient ingestion and contributes to glucose homeostasis through several parallel pathways: glucose-dependent stimulation of insulin secretion, suppression of glucagon release, slowing of gastric emptying, and central effects on satiety and food reward. Pharmacological agonists exploit this same receptor while resisting the rapid degradation that limits the native peptide to a circulating half-life of only a few minutes.

The class has a clinical history that begins with exenatide, an agonist derived from the salivary peptide exendin-4 of Heloderma suspectum, and now extends to once-weekly long-acting analogues such as semaglutide and dulaglutide and to next-generation multi-receptor agonists discussed elsewhere in this guide series. Approved indications today fall into two principal categories: glycaemic control in type 2 diabetes mellitus and chronic weight management in adults who meet body-mass-index thresholds defined by each product's labelling.

Within obesity medicine, the GLP-1 RA class has reframed pharmacotherapy. Earlier weight-loss agents typically delivered single-digit-percentage placebo-adjusted weight reduction; long-acting GLP-1 RAs at obesity-indicated doses produced double-digit reductions in pivotal trials. (Wilding et al., 2021, NEJM — PMID 33567185) These results, combined with a generally manageable safety profile, prompted regulatory approvals across multiple jurisdictions and accelerated investment in the broader incretin pipeline.

2. Endogenous GLP-1 physiology

GLP-1 is one of two principal incretin hormones, the other being glucose-dependent insulinotropic polypeptide (GIP). It is produced from the proglucagon gene by tissue-specific post-translational processing in intestinal L-cells, predominantly in the distal small intestine and colon. The major bioactive forms are GLP-1(7-37) and the slightly more abundant GLP-1(7-36)-amide. Both engage the GLP-1 receptor with comparable affinity.

Secretion and clearance

L-cell secretion is triggered by direct luminal nutrient sensing — particularly carbohydrates and lipids — and is amplified by neural and hormonal signals from more proximal segments of the gut. Once released, native GLP-1 is rapidly inactivated by the serine protease dipeptidyl peptidase-4 (DPP-4), which cleaves the N-terminal His-Ala dipeptide and produces the inactive metabolite GLP-1(9-36)-amide. The half-life of intact circulating GLP-1 is approximately 1.5 to 2 minutes, which is why pharmacological strategies have emphasised either DPP-4 inhibition (a separate drug class) or structural modification of the peptide backbone to resist proteolysis.

Receptor distribution and downstream signalling

The GLP-1 receptor is a class B G-protein-coupled receptor expressed on pancreatic beta cells, alpha cells, gastrointestinal smooth muscle, several regions of the central nervous system including the area postrema and arcuate nucleus, and at lower density in cardiac, vascular, and renal tissues. Receptor engagement activates adenylyl cyclase via Gαs, raises intracellular cyclic AMP, and stimulates protein kinase A and Epac2-dependent pathways that potentiate glucose-dependent insulin secretion. Beta-arrestin recruitment, biased agonism, and receptor desensitisation are active areas of research that may help explain pharmacodynamic differences between analogues.

Why glucose-dependence matters

The insulinotropic effect of GLP-1 receptor activation is glucose-dependent: at euglycaemic or hypoglycaemic blood-glucose concentrations, insulin release is not stimulated. This is the principal reason monotherapy with a GLP-1 RA carries a low intrinsic risk of hypoglycaemia in the absence of concomitant insulin or sulphonylurea therapy.

3. Mechanism of pharmacological agonism

Approved GLP-1 receptor agonists share a common pharmacodynamic profile but differ substantially in their pharmacokinetic engineering. Three principal strategies have been used to extend the half-life of the native peptide and produce agents suitable for once-daily or once-weekly administration.

• Exendin-4 backbone: Exenatide is based on the lizard-derived peptide exendin-4, which is naturally resistant to DPP-4 cleavage because of an alanine-to-glycine substitution at position 2. Lixisenatide is a related analogue with C-terminal modification.
• Albumin coupling: Liraglutide is a human GLP-1 analogue with a C16 fatty-acid chain attached via a glutamic acid spacer. The lipid moiety promotes reversible binding to serum albumin, which both shields the peptide from DPP-4 and slows renal clearance, supporting once-daily dosing. Semaglutide extends this strategy with a longer C18 fatty-diacid linker and substitution of alanine at position 8 with α-aminoisobutyric acid (Aib), yielding a half-life suitable for once-weekly subcutaneous administration. (Lau et al., 2015, J Med Chem — PMID 26308095)
• Fc-fusion: Dulaglutide is a covalent dimer of a modified GLP-1(7-37) peptide fused to a human IgG4 Fc fragment. The Fc fusion confers a long terminal half-life through neonatal Fc receptor-mediated recycling.

Pharmacological activation produces the same family of physiological effects as the endogenous hormone, but the magnitude and duration are amplified by sustained receptor engagement. Insulin secretion is enhanced in a glucose-dependent fashion, glucagon secretion is suppressed, gastric emptying is slowed (more pronounced with short-acting agents and subject to tachyphylaxis with long-acting agents), and central pathways governing satiety, food reward, and meal termination are engaged. The relative contribution of each pathway to the observed weight-loss effect remains an active research question, but central appetite signalling is widely regarded as the dominant driver in chronic dosing.

4. Major analogues and pharmacokinetics

The principal approved GLP-1 receptor agonists differ in their backbone, half-life, route of administration, and labelled indication. The summary below reflects the publicly available labelling at the time of writing; clinicians should consult the current prescribing information for any specific product.

Semaglutide

Marketed as Ozempic for type 2 diabetes, Wegovy for chronic weight management, and Rybelsus as an oral formulation. The injectable products are administered subcutaneously once weekly; the oral formulation is administered daily with strict dosing instructions because of its co-formulation with the absorption enhancer SNAC. Half-life is reported in the range of seven days, supporting weekly dosing. (see Wegovy / Ozempic FDA prescribing information)

Liraglutide

Marketed as Victoza for type 2 diabetes (1.2 mg and 1.8 mg) and as Saxenda for chronic weight management (3.0 mg). Once-daily subcutaneous injection. Approximate half-life is thirteen hours. (see Saxenda / Victoza FDA prescribing information)

Dulaglutide

Marketed as Trulicity for type 2 diabetes. Once-weekly subcutaneous injection. Half-life approximately five days. (see Trulicity FDA prescribing information)

Exenatide

Available as Byetta (twice-daily) and Bydureon BCise (once-weekly extended-release). Predominantly used in type 2 diabetes. Lixisenatide (Adlyxin) is a related once-daily agent.

Tirzepatide and the multi-receptor agonists

Tirzepatide is a dual GIP/GLP-1 receptor agonist marketed as Mounjaro (type 2 diabetes) and Zepbound (chronic weight management). Although it engages the GLP-1 receptor, it is a distinct pharmacological entity and is discussed in detail in the comparison and GLP-3 guides. Retatrutide, a triple GLP-1/GIP/glucagon receptor agonist, is investigational at the time of writing.

5. Approved indications and labelling

Two principal indication families dominate current labelling: glycaemic control in type 2 diabetes mellitus and chronic weight management. Cardiovascular and renal outcome data have additionally supported expanded labelling for several agents.

Type 2 diabetes mellitus

GLP-1 RAs are recommended in major diabetes-care guidelines as an option in adults with type 2 diabetes who require additional glycaemic control beyond first-line therapy, particularly when atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease coexists. (see ADA Standards of Care in Diabetes (current edition)) Magnitude of HbA1c lowering in pivotal trials has typically been in the range of 1.0 to 1.8 percentage points, with substantial inter-agent variability. (see PubMed; verification pending)

Chronic weight management

FDA-approved indications for chronic weight management include semaglutide 2.4 mg (Wegovy) and liraglutide 3.0 mg (Saxenda) in adults with a body-mass index of 30 kg/m² or greater, or 27 kg/m² or greater with at least one weight-related comorbidity. (see FDA Wegovy approval history (FDA.gov)) Tirzepatide (Zepbound) is approved under the same BMI thresholds. (see FDA Zepbound approval announcement, November 2023 (FDA.gov))

Cardiovascular and renal outcomes

Several agents in the class have demonstrated cardiovascular benefit in dedicated outcome trials. The LEADER trial established cardiovascular safety and benefit for liraglutide in adults with type 2 diabetes at high cardiovascular risk. (Marso et al., 2016, NEJM — PMID 27295427) SUSTAIN-6 reported analogous findings for semaglutide. (Marso et al., 2016, NEJM — PMID 27633186) The SELECT trial extended cardiovascular outcome data for semaglutide 2.4 mg in adults with overweight or obesity and established cardiovascular disease without type 2 diabetes. (Lincoff et al., 2023, NEJM — PMID 37952131)

6. Safety profile and class warnings

The GLP-1 RA class shares a recognisable adverse-event profile dominated by gastrointestinal symptoms, particularly during dose escalation. Nausea, vomiting, diarrhoea, constipation, and abdominal discomfort are common; tolerability is generally improved by gradual titration and meal-pattern adjustments. A separate pillar guide on side-effect management addresses these in detail.

Class boxed warning — thyroid C-cell tumours

Several GLP-1 RAs carry a boxed warning regarding the rodent finding of medullary thyroid C-cell tumours and a contraindication in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. (see Wegovy / Ozempic FDA prescribing information, Boxed Warning) The relevance of the rodent findings to humans is incompletely understood, and post-marketing surveillance has not, to date, established a causal association in humans, but the labelling-driven contraindication remains.

Pancreatitis and gallbladder disease

Acute pancreatitis has been reported in clinical trials and post-marketing surveillance. The absolute incidence is low but exceeds the placebo background in some pooled analyses. (see PubMed; verification pending) Cholelithiasis and cholecystitis are also more common in GLP-1 RA-treated populations, an effect plausibly related to gallbladder motility changes accompanying rapid weight loss.

Renal effects and hypoglycaemia

Acute kidney injury, predominantly in the setting of dehydration from gastrointestinal symptoms, has been described. Intrinsic risk of hypoglycaemia is low because of the glucose-dependent mechanism, but co-administration with insulin or sulphonylureas substantially raises that risk and typically warrants dose reduction of the background therapy. Specific clinical scenarios — diabetic retinopathy progression, gastroparesis, perioperative aspiration risk in the setting of delayed gastric emptying — are detailed in product labelling and recent professional-society statements. (see ASA Consensus-Based Guidance on Preoperative Management of GLP-1 RAs (2023))

7. Emerging directions

The success of the GLP-1 RA class has driven a wave of next-generation incretin-based therapies. Dual agonists targeting GLP-1 plus GIP (tirzepatide) have moved from investigational to approved status; triple agonists adding glucagon-receptor activity (retatrutide) are in advanced clinical development. Co-administration with amylin analogues (cagrilintide–semaglutide combinations such as CagriSema) and oral peptide formulations are similarly active fronts. (Garvey et al., 2025, NEJM — PMID 40544433)

Beyond obesity and diabetes, GLP-1 receptor pharmacology is being explored in non-alcoholic and metabolic-dysfunction-associated steatohepatitis, alcohol-use disorder, neurodegenerative disease, and chronic kidney disease. Several of these indications are supported by preliminary mechanistic and small-cohort data; large definitive trials are ongoing. The breadth of pipeline activity is one reason this class will continue to be revised and expanded over the next several years; readers interested in real-time updates should follow the live Research News feed rather than rely on a static document.

References

This guide cites primary peer-reviewed and regulatory sources where the underlying claim has been verified. A small number of supporting items remain in active verification and are listed below for transparency.

Verified primary references

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). NEJM 2021. PMID 33567185.
2. Rubino D et al. Continued Semaglutide vs Placebo on Weight Loss Maintenance (STEP 4). JAMA 2021. PMID 33755728.
3. Marso SP et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). NEJM 2016. PMID 27295427.
4. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Type 2 Diabetes (SUSTAIN-6). NEJM 2016. PMID 27633186.
5. Lincoff AM et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). NEJM 2023. PMID 37952131.
6. Lau J et al. Discovery of the Once-Weekly GLP-1 Analogue Semaglutide. J Med Chem 2015. PMID 26308095.
7. Garvey WT et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE-1). NEJM 2025. PMID 40544433.

Still seeking primary citation

• Magnitude of HbA1c reduction in head-to-head GLP-1 RA trials — meta-analysis (verification pending)
• Incidence of acute pancreatitis in pooled GLP-1 RA trials — meta-analysis (verification pending)
• ADA Standards of Care recommendation language for GLP-1 RA in T2DM with established CVD (current edition)
• ASA / multi-society perioperative GLP-1 RA guidance (2023 consensus)
• FDA Wegovy adolescent indication approval letter (FDA.gov)
• FDA Zepbound approval announcement, November 2023 (FDA.gov)
• Wegovy / Ozempic FDA prescribing information — Boxed Warning text and pharmacokinetic parameters
• Saxenda / Victoza FDA prescribing information — pharmacokinetic parameters
• Trulicity FDA prescribing information — pharmacokinetic parameters